MedPath

The effect of Morus nigra extract on patients with liver cirrhosis

Phase 2
Conditions
iver cirrhosis.
Fibrosis and cirrhosis of liver
Registration Number
IRCT20140301016776N3
Lead Sponsor
Mashhad University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
80
Inclusion Criteria

Patients with liver cirrhosis awaiting liver transplantation

Exclusion Criteria

Hepatocellular carcinoma or other malignancy
History of liver transplantation
Alcoholic drink
Variceal bleeding
Portal vein thrombosis
Pregnancy

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
MELD index. Timepoint: Before intervention and end of the study. Method of measurement: The MELD index is determined by total bilirubin, serum creatinine, and INR (9.57 Ln(Creat) + 3.78 Ln(bili) + 11.2 Ln(INR) + 6.43).
Secondary Outcome Measures
NameTimeMethod
Child-Pugh. Timepoint: before intervention and at the end of study. Method of measurement: This index is calculated based on total bilirubin, albumin, INR, ascites and encephalopathy.;Patient survival. Timepoint: One year after enrollment. Method of measurement: Record the number of patient deaths.;Liver enzymes. Timepoint: Before intervention and at the end of study. Method of measurement: Fasting blood test.
© Copyright 2025. All Rights Reserved by MedPath